-
Something wrong with this record ?
Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet
I. Dostálová, T. Roubíček, M. Bártlová, M. Mráz, Z. Lacinová, D. Haluzíková, P. Kaválková, M. Matoulek, M. Kasalický, M. Haluzík
Language English Country Great Britain
Document type Controlled Clinical Trial, Research Support, Non-U.S. Gov't
Grant support
NR8302
MZ0
CEP Register
Digital library NLK
Full text - Část
Source
NLK
Open Access Digital Library
from 1948-06-01
Open Access Digital Library
from 1997-07-01
- MeSH
- Diabetes Mellitus, Type 2 diet therapy genetics blood MeSH
- Diet MeSH
- Adult MeSH
- Weight Loss genetics MeSH
- Thinness genetics metabolism MeSH
- Caloric Restriction MeSH
- Middle Aged MeSH
- Humans MeSH
- RNA, Messenger metabolism MeSH
- Obesity diet therapy genetics blood MeSH
- Growth Differentiation Factor 15 genetics blood metabolism MeSH
- Body Weight physiology MeSH
- Adipose Tissue metabolism MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Controlled Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
OBJECTIVE: Macrophage inhibitory cytokine-1 (MIC-1) is a novel regulator of energy homeostasis. We explored whether alterations in MIC-1 levels contribute to metabolic disturbances in patients with obesity and/or obesity and type 2 diabetes mellitus (T2DM). DESIGN: We measured serum MIC-1 levels and its mRNA expression in subcutaneous and visceral adipose tissue of 17 obese nondiabetic women, 14 obese women with T2DM and 23 healthy lean women. We also explored the relationship of MIC-1 with anthropometric and biochemical parameters and studied the influence of 2-week very low calorie diet (VLCD) on serum MIC-1 levels. METHODS: Serum MIC-1 levels were measured by ELISA and its mRNA expression was determined by RT-PCR. RESULTS: Both obese and T2DM group had significantly elevated serum MIC-1 levels relative to controls. T2DM group had significantly higher serum MIC-1 levels relative to obese group. Serum MIC-1 positively correlated with body weight, body fat, and serum levels of triglycerides, glucose, HbAlc, and C-reactive protein and it was inversely related to serum high-density lipoprotein cholesterol. Fat mRNA MIC-1 expression did not significantly differ between lean and obese women but it was significantly higher in subcutaneous than in visceral fat in both groups. VLCD significantly increased serum MIC-1 levels in obese but not T2DM group. CONCLUSION: Elevated MIC-1 levels in patients with obesity are further increased by the presence of T2DM. We suggest that in contrast to patients with cancer cachexia, increased MIC-1 levels in obese patients and diabetic patients do not induce weight loss.
References provided by Crossref.org
- 000
- 03867naa 2200565 a 4500
- 001
- bmc11019491
- 003
- CZ-PrNML
- 005
- 20221005141255.0
- 008
- 110714s2009 xxk e eng||
- 009
- AR
- 024 7_
- $a 10.1530/EJE-09-0417 $2 doi
- 035 __
- $a (PubMed)19515791
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Dostálová, Ivana $7 xx0075775
- 245 10
- $a Increased serum concentrations of macrophage inhibitory cytokine-1 in patients with obesity and type 2 diabetes mellitus: the influence of very low calorie diet / $c I. Dostálová, T. Roubíček, M. Bártlová, M. Mráz, Z. Lacinová, D. Haluzíková, P. Kaválková, M. Matoulek, M. Kasalický, M. Haluzík
- 314 __
- $a 3rd Department of Medicine, 1st Faculty of Medicine, Charles University and General University Hospital, U Nemocnice 1, 128 00 Prague 2, Czech Republic.
- 520 9_
- $a OBJECTIVE: Macrophage inhibitory cytokine-1 (MIC-1) is a novel regulator of energy homeostasis. We explored whether alterations in MIC-1 levels contribute to metabolic disturbances in patients with obesity and/or obesity and type 2 diabetes mellitus (T2DM). DESIGN: We measured serum MIC-1 levels and its mRNA expression in subcutaneous and visceral adipose tissue of 17 obese nondiabetic women, 14 obese women with T2DM and 23 healthy lean women. We also explored the relationship of MIC-1 with anthropometric and biochemical parameters and studied the influence of 2-week very low calorie diet (VLCD) on serum MIC-1 levels. METHODS: Serum MIC-1 levels were measured by ELISA and its mRNA expression was determined by RT-PCR. RESULTS: Both obese and T2DM group had significantly elevated serum MIC-1 levels relative to controls. T2DM group had significantly higher serum MIC-1 levels relative to obese group. Serum MIC-1 positively correlated with body weight, body fat, and serum levels of triglycerides, glucose, HbAlc, and C-reactive protein and it was inversely related to serum high-density lipoprotein cholesterol. Fat mRNA MIC-1 expression did not significantly differ between lean and obese women but it was significantly higher in subcutaneous than in visceral fat in both groups. VLCD significantly increased serum MIC-1 levels in obese but not T2DM group. CONCLUSION: Elevated MIC-1 levels in patients with obesity are further increased by the presence of T2DM. We suggest that in contrast to patients with cancer cachexia, increased MIC-1 levels in obese patients and diabetic patients do not induce weight loss.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a tuková tkáň $x metabolismus $7 D000273
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a tělesná hmotnost $x fyziologie $7 D001835
- 650 _2
- $a kalorická restrikce $7 D031204
- 650 _2
- $a diabetes mellitus 2. typu $x dietoterapie $x genetika $x krev $7 D003924
- 650 _2
- $a dieta $7 D004032
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a růstový diferenciační faktor 15 $x genetika $x krev $x metabolismus $7 D055436
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a obezita $x dietoterapie $x genetika $x krev $7 D009765
- 650 _2
- $a messenger RNA $x metabolismus $7 D012333
- 650 _2
- $a hubenost $x genetika $x metabolismus $7 D013851
- 650 _2
- $a hmotnostní úbytek $x genetika $7 D015431
- 655 _2
- $a klinické zkoušky kontrolované $7 D018848
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a klinické zkoušky kontrolované $7 D018848
- 700 1_
- $a Roubíček, Tomáš, $7 xx0104676 $d 1982-
- 700 1_
- $a Bártlová, Markéta $7 xx0119174
- 700 1_
- $a Mráz, Miloš $7 xx0119173
- 700 1_
- $a Lacinová, Zdeňka $7 xx0062138
- 700 1_
- $a Haluzíková, Denisa, $d 1970- $7 jo2003163140
- 700 1_
- $a Kaválková, Petra $7 xx0094376
- 700 1_
- $a Matoulek, Martin, $d 1972- $7 xx0080325
- 700 1_
- $a Kasalický, Mojmír, $d 1959- $7 mzk2007395028
- 700 1_
- $a Haluzík, Martin, $d 1970- $7 xx0000707
- 773 0_
- $t European Journal of Endocrinology $w MED00009634 $g Roč. 161, č. 3 (2009), s. 397-404
- 856 41
- $u https://eje.bioscientifica.com/doi/10.1530/EJE-09-0417 $y plný text volně přístupný
- 910 __
- $a ABA008 $b x $y 2 $z 0
- 990 __
- $a 20110715114007 $b ABA008
- 991 __
- $a 20221005141250 $b ABA008
- 999 __
- $a ok $b bmc $g 864451 $s 729367
- BAS __
- $a 3
- BMC __
- $a 2009 $x MED00009634 $b 161 $c 3 $d 397-404 $m European journal of endocrinology $n Eur J Endocrinol
- GRA __
- $a NR8302 $p MZ0
- LZP __
- $a 2011-3B09/Bjvme